Crinetics Pharmaceuticals Statistics Share Statistics Crinetics Pharmaceuticals has 93.68M
shares outstanding. The number of shares has increased by 17.05%
in one year.
Shares Outstanding 93.68M Shares Change (YoY) 17.05% Shares Change (QoQ) 0.68% Owned by Institutions (%) 99.99% Shares Floating 87.18M Failed to Deliver (FTD) Shares 84 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 12.24M, so 13.06% of the outstanding
shares have been sold short.
Short Interest 12.24M Short % of Shares Out 13.06% Short % of Float 14.87% Short Ratio (days to cover) 15.02
Valuation Ratios The PE ratio is -13.84 and the forward
PE ratio is -5.85.
Crinetics Pharmaceuticals's PEG ratio is
0.
PE Ratio -13.84 Forward PE -5.85 PS Ratio 3975.39 Forward PS 56.6 PB Ratio 3.12 P/FCF Ratio -17.97 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Crinetics Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 23.04,
with a Debt / Equity ratio of 0.04.
Current Ratio 23.04 Quick Ratio 23.04 Debt / Equity 0.04 Debt / EBITDA -0.15 Debt / FCF -0.23 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $2.38K Profits Per Employee $-682.86K Employee Count 437 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -44.74% in the
last 52 weeks. The beta is 0.33, so Crinetics Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.33 52-Week Price Change -44.74% 50-Day Moving Average 30.6 200-Day Moving Average 39.1 Relative Strength Index (RSI) 34.55 Average Volume (20 Days) 824,853
Income Statement In the last 12 months, Crinetics Pharmaceuticals had revenue of 1.04M
and earned -298.41M
in profits. Earnings per share was -3.69.
Revenue 1.04M Gross Profit -1.75M Operating Income -338.85M Net Income -298.41M EBITDA -338.85M EBIT -338.85M Earnings Per Share (EPS) -3.69
Full Income Statement Balance Sheet The company has 264.55M in cash and 51.72M in
debt, giving a net cash position of 212.82M.
Cash & Cash Equivalents 264.55M Total Debt 51.72M Net Cash 212.82M Retained Earnings -952.11M Total Assets 1.36B Working Capital 1.23B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -225.97M
and capital expenditures -3.84M, giving a free cash flow of -229.81M.
Operating Cash Flow -225.97M Capital Expenditures -3.84M Free Cash Flow -229.81M FCF Per Share -2.84
Full Cash Flow Statement Margins Gross margin is -168.05%, with operating and profit margins of -32613.47% and -28720.69%.
Gross Margin -168.05% Operating Margin -32613.47% Pretax Margin -28720.69% Profit Margin -28720.69% EBITDA Margin -32613.47% EBIT Margin -32613.47% FCF Margin -22118.77%
